https://doi.org/10.18502/jovr.v19i1.15436
statistics
- 211 Abstract Views
- 145 PDF Views
- 0 HTML Views
authors
-
Farkhondeh Chaharband
Farkhondeh Chaharband
Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
-
Reyhaneh Varshochian
Reyhaneh Varshochian
Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
-
Rassoul Dinarvand
Rassoul Dinarvand
Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
-
Hamideh Sabbaghi
Hamideh Sabbaghi
Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
-
Mozhgan Rezaei Kanavi
Mozhgan Rezaei Kanavi
Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
-
Narsis Daftarian
Narsis Daftarian
Ocular Tissue Engineering Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
-
Ramin Nourinia
Ramin Nourinia
Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Published Date
- Mar 10, 2024
Polymeric Propranolol Nanoparticles for Intraocular Delivery: Formulation, Characterization, and Vitreous Pharmacokinetics
Abstract
Purpose: Recent studies have reported the promising effect of intravitreal propranolol on retinal neovascularization. However, rapid clearance and short half-life of the drug in the vitreous are the main drawbacks of this therapeutic approach. This study investigates the extension of the residence time of propranolol in the vitreous by polymeric nanoparticles (NPs) with the prospect of improving choroidal neovascularization treatment.
Methods: The poly (lactic-co-glycolic) acid (PLGA) NPs were fabricated by a modified double emulsion solvent evaporation method and the obtained NPs were characterized for their size, poly dispersity index (PDI), and surface image. The in vitro release, cell cytotoxicity, and uptake of NPs were also evaluated. To investigate the effect of the vitreous pharmacokinetic drug loaded NPs versus that of the free propranolol, they were intravitreally injected into the rabbits’ eyes and the drug vitreous concentrations in defined intervals were analyzed by high performance liquid chromatography (HPLC).
Results: The spherical NPs with about 230 nm size, and almost 10% drug loading were obtained. Based on the 3-(4, 5-Dimethylthiazol-2-Yl)-2, 5-Diphenyltetrazolium Bromide (MTT) outcomes, 30 µg/ml of propranolol was considered as the guide dosage in the intravitreal injection. Confocal microscopy images verified the presence of labeled NPs in the posterior segment after five days of receiving the injection. In vivo assay revealed that the vanishing rate of propranolol in rabbits treated with propranolol NPs was reduced at twice the rate as compared to that of the vanishing rate experienced with only the free drug.
Conclusion: PLGA NPs can prolong the existence of propranolol in both vitreous and posterior ocular tissues, and thus, may provide an effective approach in treatment of posterior segment neovascularization.
Keywords:
Ocular Neovascularization, Pharmacokinetic, PLGA Nanoparticles, Propranolol Vitreous
References
2. Kasiri A. Inhibition of corneal neovascularization by topically administered propranolol in a rabbit model. AJPS 2017;11.
3. Omri S, Tahiri H, Pierre WC, Desjarlais M, Lahaie I, Loiselle S-E, et al. Propranolol attenuates proangiogenic activity of mononuclear phagocytes: Implication in choroidal neovascularization. Invest Ophthalmol Vis Sci 2019;60:4632–4642.
4. Lavine JA, Farnoodian M, Wang S, Darjatmoko SR, Wright LS, Gamm DM, et al. b2–adrenergic receptor antagonism attenuates CNV through inhibition of VEGF and IL-6 expression. Invest Ophthalmol Vis Sci 2017;58:299–308.
5. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–e116.
6. Bainbridge JW, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher AJ, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 2002;9:320–326.
7. Bressler SB. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009;116:S1–S7.
8. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med Mol Imaging 2003;47:149–149.
9. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest 2014;124:1430–1438.
10. Marano RJ, Rakoczy PE. Treatments for choroidal and retinal neovascularization: A focus on oligonucleotide therapy and delivery for the regulation of gene function. Clin Exp Ophthalmol 2005;33:81–89.
11. Nourinia R, Soheili ZS, Ahmadieh H, Akrami H, Rezaei Kanavi M, Samiei S. Knockdown of the placental growth factor gene inhibits laser induced choroidal neovascularization in a murine model. J Ophthalmic Vis Res 2013;8:4–8.
12. Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: What’s new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res 2016;103:253–269.
13. Lamy S, Lachambre MP, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: Inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010;53:200–208.
14. Fangueiro JF, Silva AM, Garcia ML, Souto EB. Current nanotechnology approaches for the treatment and management of diabetic retinopathy. Eur J Pharm Biopharm 2015;95:307–322.
15. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, et al. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Biomaterials 2013;34:7544–7551.
16. Kompella UB, Amrite AC, Ravi RP, Durazo SA. Nanomedicines for back-of-the-eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013;36:172–198.
17. Shen HH, Chan EC, Lee JH, Bee YS, Lin TW, Dusting GJ, et al. Nanocarriers for treatment of ocular neovascularization in the back of the eye: New vehicles for ophthalmic drug delivery. Nanomedicine 2015;10:2093–2107.
18. Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, et al. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 2013;50:341–352.
19. Chaharband F, Kamalinia G, Atyabi F, Mortazavi SA, Mirzaie ZH, Dinarvand R. Formulation and in vitro evaluation of curcumin-lactoferrin conjugated nanostructures for cancerous cells. Artif Cells Nanomed Biotechnol 2018;46:626–636.
20. Jiang G, Jia H, Qiu J, Mo Z, Wen Y, Zhang Y, et al. PLGA nanoparticle platform for trans-ocular barrier to enhance drug delivery: A comparative study based on the application of oligosaccharides in the outer membrane of carriers. Int J Nanomedicine 2020;15:9373–9387.
21. Tahiri H, Omri S, Lahaie I, Chemtob S. Implication of betaadrenergic receptor in choroidal neovascularization. Ann Eye Sci 2018;3:AB033.
22. Karimi S, Nikkhah H, Ahmadieh H, Safi S. Intravitreal injection of propranolol for the treatment of retinal capillary hemangioma in a case of von Hippel-lindau. Retin Cases Brief Rep 2020;14:305–309.
23. Varshochian R, Riazi-Esfahani M, Jeddi-Tehrani M, Mahmoudi AR, Aghazadeh S, Mahbod M, et al. Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A 2015;103:3148–3156.